Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anal Cancer
Research in the area of anal cancer reported from S.K. Mai and colleagues
June 9th, 2009
According to recent research from Mannheim, Germany, "To investigate whether a dose reduction to CT-enlarged but FDG-PET-negative (([F-18]-fluoro-2-deoxy-D-glucose positron emission tomography) inguinal lymph nodes in radiochemotherapy of anal cancer is safe. 39 sequential patients with anal cancer (mean age 59 years [range: 37-86 years], median follow-up 26 months [range: 3-51 months]) receiving pretherapeutic FDG-PET were included. All patients were treated with combined radiochemotherapy including elective radiation of the inguinal lymph nodes with 36 Gy." "In case of involvement (FDG-PET positivity defined as normalized SUV [standard uptake value] above Delta >...
Source: Cancer Weekly (2009-06-09)
|
